Latest Breaking News On - Rare severe disease priority review designation - Page 1 : vimarsana.com

- Trodelvy is Everest's First Product to Receive Regulatory Approval in China - - Everest Plans to Launch Commercial Sales of Trodelvy in China in Q4 2022 - - Conference call will be held to discuss the approval- SHANGHAI, June 10, 2022 /PRNewswire/ Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that China's National Medical Products Administration (NMPA) has approved Trodelvy (sacituzumab govitecan or SG) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. This is the first drug that Everest has obtained New Drug Application (NDA) approval to launch in China. In May 2021, the NMPA accepted Eve

Yang shiUnited statesHong kongHong kong special administrative regionHong kong generalSouth koreaBinghe xuAsia pacificKevin guoTrodelvy sacituzumab govitecanKerry blanchardHealth sciences authority of singaporeDrug administrationNational new drug antiCancer clinical research centreGilead sciences inc